KDR and glioblastoma: The VEGFR inhibitor sorafenib was investigated in combination with the mTOR inhibitor temsirolimus and the EGFR inhibitor erlotinib in two different phase I/II adult GBM trials, and did not show efficacy in either trial (89, 90).